JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

VEGFR

VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.

A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
A3022 Pazopanib (GW-786034)

Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
A3750 Regorafenib hydrochloride

Target: Raf|VEGFR|PDGFR|c-Kit|c-RET

Summary: Tyrosine kinase inhibitor

≥25.95 mg/mL
A3843 SU 5402

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR2/FGFR/PDGFR/EGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL
A3847 SU5416

Target: VEGFR

Summary: VEGF receptor inhibitor and AHR agonist

insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL
B5864 Fruquintinib(HMPL-013)

Target: VEGFR

Summary: Potent and selective inhibitor of VEGFR 1, 2, 3

insoluble in H2O; insoluble in EtOH; ≥6.35 mg/mL
A8313 RAF265

Target: Raf|VEGFR

Summary: Multiple intracellular kinases inhibitor

≥25.9 mg/mL
A8370 Axitinib (AG 013736)
1 Citation

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR1/ c-Kit inhibitor

insoluble in H2O; ≥19.3 mg/mL
A8550 Telatinib (BAY 57-9352)

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor

insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL
A8555 Vandetanib (ZD6474)

Target: VEGFR|EGFR

Summary: VEGFR2/EGFR antagonist

insoluble in H2O; ≥11.88 mg/mL